CDC NEWS


powered by Surfing Waves


Latest News


What You Need to Know about Variants


27 Nov 2021

Omicron Variant No cases of this variant have been identified in the U.S. to date. CDC is following the details of this new variant. See CDC’s Media Statement.


Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters


19 Nov 2021

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals 18 years of age and older after completion of primary vaccination with any FDA-authorized or approved COVID-19 vaccine. The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices will meet later today to discuss further clinical recommendations.


Moderna COVID-19 booster may protect against variants


03 Nov 2021

At a Glance A booster of the Moderna COVID-19 vaccine increased levels of neutralizing antibodies against all variants of concern in a primate study. The findings suggest that COVID-19 boosters not only lengthen immunity but help broaden and strengthen the immune response.


DC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years


02 Nov 2021

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation that children 5 to 11 years old be vaccinated against COVID-19 with the Pfizer-BioNTech pediatric vaccine. CDC now expands vaccine recommendations to about 28 million children in the United States in this age group and allows providers to begin vaccinating them as soon as possible.


Breakthrough Infections Occur in Those with Lower Antibody Levels, Israeli Study Shows


26 Oct 2021

To see how COVID-19 vaccines are working in the real world, Israel has provided particularly compelling data. The fact that Israel is relatively small, keeps comprehensive medical records, and has a high vaccination rate with a single vaccine (Pfizer) has contributed to its robust data collection. Now, a new Israeli study offers some insight into those relatively uncommon breakthrough infections. It confirms that breakthrough cases, as might be expected, arise most often in individuals with lower levels of neutralizing antibodies.




Articles


Four Vaccine Doses Prevented Severe Omicron COVID-19 Better Than 3


10 May 2022

Older patients in Israel who received a fourth dose of the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine were more than 3 times less likely to develop severe COVID-19 than those who received only 3 doses. But while protection against severe disease did not wane during the testing period, protection against confirmed infection appeared short-lived.




Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19


20 Apr 2022

Risk of SARS-CoV-2 reinfection among unvaccinated people with prior COVID-19 is a subject of debate.1,2 We performed a survival analysis in a large US population to assess the degree and duration of protection associated with natural immunity in unvaccinated individuals.




Myocarditis Adverse Event Less Common After COVID-19 Vaccine Booster


12 Apr 2022

The risk of adolescents developing myocarditis is lower after a booster dose of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine than after the second dose, according to a CDC analysis of data from the Vaccine Adverse Event Reporting System (VAERS). Myocarditis is a rare but serious adverse event associated with COVID-19 mRNA vaccination. To assess whether this adverse event was also associated with booster doses administered to adolescents, the authors analyzed reports submitted to the VAERS system and v-safe between December 9, 2021, and February 20, 2022.




Even Mild COVID-19 May Change the Brain


23 Mar 2022

Alarge study comparing brain scans from the same individuals before and after SARS-CoV-2 infection suggests that brain changes could be a lingering outcome of even mild COVID-19. Writing in Nature, researchers at Oxford University’s Wellcome Centre for Integrative Neuroimaging reported that several months after study participants had SARS-CoV-2 infections, they had more gray matter loss and tissue abnormalities, mainly in the areas of the brain associated with smell, and more brain size shrinkage than participants who hadn’t been infected with the virus.




Risks and burdens of incident diabetes in long COVID: a cohort study


21 Mar 2022

Background There is growing evidence suggesting that beyond the acute phase of SARS-CoV-2 infection, people with COVID-19 could experience a wide range of post-acute sequelae, including diabetes. However, the risks and burdens of diabetes in the post-acute phase of the disease have not yet been comprehensively characterised. To address this knowledge gap, we aimed to examine the post-acute risk and burden of incident diabetes in people who survived the first 30 days of SARS-CoV-2 infection. Interpretation In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical control group from a pre-pandemic era. Post-acute COVID-19 care should involve identification and management of diabetes.




Enroll for Free